Jiangsu Nhwa Pharmaceutical Co., LTD (SHE:002262)
China flag China · Delayed Price · Currency is CNY
22.72
-0.05 (-0.22%)
Feb 3, 2026, 11:34 AM CST

SHE:002262 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Jan '23 Jan '22 Dec '20
Operating Revenue
5,9645,6384,9764,2553,9193,344
Other Revenue
59.6159.6165.6343.4916.5316.99
6,0235,6985,0424,2993,9363,361
Revenue Growth (YoY)
8.90%13.01%17.29%9.22%17.09%-18.99%
Cost of Revenue
1,5301,5461,4031,037932.68843.14
Gross Profit
4,4944,1523,6383,2623,0032,518
Selling, General & Admin
2,4512,2441,9441,8471,7431,443
Research & Development
672.67595.65549.32454.25351.73245.86
Other Operating Expenses
64.9265.6560.257.4654.0445.61
Operating Expenses
3,2172,9392,5692,3602,1561,737
Operating Income
1,2771,2131,070901.63847.28781.53
Interest Expense
-2.79-4.03-4.16-4.95-5.06-1.59
Interest & Investment Income
92.587.8274.8561.853.9248.32
Currency Exchange Gain (Loss)
0.170.170.410.91-1.14-0.38
Other Non Operating Income (Expenses)
5.63-1.9-0.74-3.19-1.621.43
EBT Excluding Unusual Items
1,3721,2951,140956.2893.38829.31
Impairment of Goodwill
------0.82
Gain (Loss) on Sale of Assets
0.30.290.150.37-0.24-0.15
Asset Writedown
4.070.070.22-0.28-0.74-0.21
Other Unusual Items
0.990.9928.3233.6223.3822.35
Pretax Income
1,3781,2971,169989.91915.78850.48
Income Tax Expense
149.07155.9134.4109.82117.75123.37
Earnings From Continuing Operations
1,2291,1411,034880.09798.02727.1
Minority Interest in Earnings
0.722.772.6720.62-0.241.72
Net Income
1,2301,1441,037900.71797.78728.82
Net Income to Common
1,2301,1441,037900.71797.78728.82
Net Income Growth
4.96%10.29%15.12%12.90%9.46%9.88%
Shares Outstanding (Basic)
1,0161,0121,0071,0121,0101,012
Shares Outstanding (Diluted)
1,0161,0121,0071,0121,0101,012
Shares Change (YoY)
0.61%0.53%-0.53%0.22%-0.24%0.72%
EPS (Basic)
1.211.131.030.890.790.72
EPS (Diluted)
1.211.131.030.890.790.72
EPS Growth
4.33%9.71%15.73%12.66%9.72%9.09%
Free Cash Flow
513.01466.07634.31533.27495.01979.74
Free Cash Flow Per Share
0.510.460.630.530.490.97
Dividend Per Share
0.3600.3600.3200.2000.2000.100
Dividend Growth
12.50%12.50%60.00%-100.00%-
Gross Margin
74.61%72.87%72.17%75.88%76.30%74.92%
Operating Margin
21.20%21.29%21.22%20.97%21.53%23.25%
Profit Margin
20.41%20.07%20.57%20.95%20.27%21.68%
Free Cash Flow Margin
8.52%8.18%12.58%12.41%12.58%29.15%
EBITDA
1,4401,3641,2051,025959.57878.36
EBITDA Margin
23.91%23.95%23.90%23.84%24.38%26.13%
D&A For EBITDA
163.17151.16135.14123.12112.2896.83
EBIT
1,2771,2131,070901.63847.28781.53
EBIT Margin
21.20%21.29%21.22%20.97%21.53%23.25%
Effective Tax Rate
10.82%12.02%11.50%11.09%12.86%14.51%
Revenue as Reported
6,0235,6985,0424,2993,9363,361
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.